Karyopharm Therapeutics (KPTI) EBT (2016 - 2025)
Historic EBT for Karyopharm Therapeutics (KPTI) over the last 14 years, with Q4 2025 value amounting to -$102.3 million.
- Karyopharm Therapeutics' EBT fell 23021.73% to -$102.3 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$196.0 million, marking a year-over-year decrease of 15638.83%. This contributed to the annual value of -$196.0 million for FY2025, which is 15638.83% down from last year.
- As of Q4 2025, Karyopharm Therapeutics' EBT stood at -$102.3 million, which was down 23021.73% from -$33.1 million recorded in Q3 2025.
- Over the past 5 years, Karyopharm Therapeutics' EBT peaked at $38.6 million during Q4 2021, and registered a low of -$102.3 million during Q4 2025.
- In the last 5 years, Karyopharm Therapeutics' EBT had a median value of -$36.7 million in 2022 and averaged -$35.3 million.
- Per our database at Business Quant, Karyopharm Therapeutics' EBT skyrocketed by 18902.19% in 2021 and then plummeted by 25596.63% in 2025.
- Quarter analysis of 5 years shows Karyopharm Therapeutics' EBT stood at $38.6 million in 2021, then crashed by 201.88% to -$39.3 million in 2022, then dropped by 6.69% to -$42.0 million in 2023, then increased by 26.18% to -$31.0 million in 2024, then plummeted by 230.22% to -$102.3 million in 2025.
- Its last three reported values are -$102.3 million in Q4 2025, -$33.1 million for Q3 2025, and -$37.2 million during Q2 2025.